This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); TRAIL receptor 2 (TRAIL-R2)	<p>Cell culture studies suggest wogonin and its related flavone derivatives could help overcome TRAIL resistance in cancer. In two TRAIL-resistant human adult T cell leukemia and lymphoma cell lines, wogonin and two related flavones, apigenin and chrysin, each increased apoptosis-inducing TRAIL-R2 expression compared with no treatment. The molecules also produced dose-dependent increases in TRAIL-induced apoptosis compared with no treatment. Next steps could include developing optimized derivatives of wogonin or its related flavones and evaluating them in models of TRAIL-resistant cancer.</p> <p>Conatumumab, a human mAb that binds to the extracellular domain of human TRAIL-R2 from Amgen Inc. and Takeda Pharmaceutical Co. Ltd., is in Phase II testing for colorectal cancer and Phase I/II testing for sarcoma and other solid tumors.</p> <p>SciBX 4(47); doi:10.1038/scibx.2011.1321 Published online Dec. 8, 2011</p>	Patent and licensing status unavailable	<p>Ding, J. <i>et al. J. Biol. Cell</i>; published online Nov. 15, 2011; doi:10.1074/jbc.M111.286526</p> <p>Contact: Min Li-Weber, German Cancer Research Center, Heidelberg, Germany e-mail: m.li-weber@dkfz-heidelberg.de</p>